[ad_1]
ABIVAX Société Anonyme (NASDAQ:ABVX) Shareholder/Analyst Name October 6, 2025 9:00 AM EDT
Firm Members
Patrick Malloy – Senior Vice President of Investor Relations
Marc M. de Garidel – CEO & Director
Chris Rabbat – VP & World Head of Medical Affairs
Fabio Cataldi – Chief Medical Officer
Convention Name Members
Marla C. Dubinsky, MD
Yatin Suneja – Guggenheim Securities, LLC, Analysis Division
Julian Harrison – BTIG, LLC, Analysis Division
Samuel Slutsky – LifeSci Capital, LLC, Analysis Division
Jason Butler – Residents JMP Securities, LLC, Analysis Division
Thomas Smith – Leerink Companions LLC, Analysis Division
Judah Frommer – Morgan Stanley, Analysis Division
Sebastiaan van der Schoot
Yale Jen – Laidlaw & Firm (UK) Ltd., Analysis Division
Presentation
Operator
Good day, and thanks for standing by. Welcome to the ABIVAX administration name to debate late-breaking ABTECT at UEG Convention. [Operator Instructions] Please be suggested that as we speak’s convention is being recorded.
I’d now like handy the convention over to your speaker as we speak, Pat Malloy. Please go forward.
Patrick Malloy
Senior Vice President of Investor Relations
Nice. Thanks, Sandra, and good morning and good afternoon to all people, and thanks for becoming a member of as we speak’s name to debate the outcomes of the late-breaking ABTECT introduced at this week’s UEG assembly in Berlin. Becoming a member of me on as we speak’s name are our Chief Government Officer, Marc de Garidel; Chief Medical Officer, Fabio Cataldi; Chief Monetary Officer, Didier Blondel; and Head of Medical Affairs, Chris Rabbat.
We’re additionally lucky to have Dr. Marla Dubinsky becoming a member of us as we speak to supply an summary of the information introduced at [ UEGW ]. Dr. Dubinsky is a Professor of Pediatrics and Drugs and Co-Director of the Susan and Leonard Feinstein IBD Medical Heart at Mount Sinai Hospital. Following Dr. Dubinsky’s presentation, we’ll transfer to a Q&A session.
Earlier than I hand the decision over to Marc to make some
[ad_2]
